Sun Pharma Secures South African Approval for Generic Semaglutide

Sun Pharmaceutical Industries has received approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection in South Africa. The approval covers treatment for adults with inadequately controlled type 2 diabetes mellitus, to be used alongside diet and exercise. Sun Pharma said it planned to launch the product in the South African market in the coming days. :contentReference[oaicite:0]{index=0}

A New Market for Sun Pharma’s Semaglutide

South Africa becomes the second market, after India, where Sun Pharma has received approval for its generic semaglutide. The development expands the company's presence in the complex-generic medicines segment and supports its strategy of making such therapies available across international markets.

Two Strengths in a Pre-Filled Pen

The approved product will be supplied as a pre-filled, multi-dose injectable pen in two strengths. The presentation is designed for flexible once-weekly dosing, giving healthcare professionals two dosage options for treatment.

◆ 2 mg / 1.5 mL

◆ 4 mg / 3 mL

◆ Dosage Form: Pre-filled, multi-dose injectable pen

◆ Dosing: Once-weekly administration

◆ Indication: Adults with inadequately controlled type 2 diabetes mellitus

Addressing Type 2 Diabetes in South Africa

Sun Pharma's announcement comes as South Africa continues to face a growing burden of type 2 diabetes associated with factors including urbanization and changing lifestyles. Greater access to established treatment options is an important part of addressing the increasing demand for diabetes care

Why the Approval Is Significant

The South African approval demonstrates Sun Pharma's ability to develop and obtain regulatory clearance for complex generic medicines in multiple markets. The company's Q1 FY27 results also highlighted recent semaglutide approvals in India, Brazil and South Africa as evidence of its capabilities in developing complex peptide products for global markets.

The Wider Opportunity for Complex Generics

Semaglutide is a peptide-based medicine, making its development and manufacturing more technically demanding than many conventional generic medicines. Sun Pharma's expansion into multiple markets indicates a broader focus on complex products where formulation, manufacturing capability and regulatory expertise are important factors.